Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue

被引：0
|
作者：
Zidan, J.
Mzalbat, R.
Shnaider, J.
Sharabi, A.
机构：
[1] Sieff Hosp, Safed, Israel
[2] Ziv Med Ctr, Safed, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11066
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer
    Hong-Zhi Shi
    Yu-Ning Wang
    Xiao-Hui Huang
    Ke-Cheng Zhang
    Hong-Qing Xi
    Jian-Xin Cui
    Guo-Xiao Liu
    Wen-Tao Liang
    Bo Wei
    Lin Chen
    World Journal of Gastroenterology, 2017, (10) : 1836 - 1842
  • [42] Comparison of the seric dosage of HER2 extracellular domain with hyperexpression-amplification of HER2 studied on metastasis biopsies of breast cancers
    Thery, J. C.
    Picquenot, J. M.
    Cornic, M.
    Lamarche, C.
    Raillot, V
    Laberge-Le-Couteulx, S.
    Veyret, C.
    Basuvau, J. P.
    Blot, E.
    BULLETIN DU CANCER, 2008, 95 (06) : 607 - 608
  • [43] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [44] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [45] SUCCESSFUL USE OF HER2 TARGETED AGENTS IN PATIENTS WITH HEAVILY PRETREATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTING WITH ELEVATED SERUM LEVELS OF THE HER2 EXTRACELLULAR DOMAIN AND/OR HER2 OVEREXPRESSING CIRCULATING TUMOR CELLS
    Kurbacher, Christian Martin
    Quade, Annegret
    Kunstmann, Gerhard
    Herz, Susanne
    Kurbacher, Jutta Anna
    Warm, Matthias R.
    BREAST, 2015, 24 : S70 - S70
  • [46] Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
    Colomer, R
    Montero, S
    Lluch, A
    Ojeda, B
    Barnadas, A
    Casado, A
    Massutí, B
    Cortés-Funes, H
    Lloveras, B
    CLINICAL CANCER RESEARCH, 2000, 6 (06) : 2356 - 2362
  • [47] Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
    Kurbacher, C. M.
    Quade, A.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [48] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Lauterlein, Jens-Jacob L.
    Petersen, Eva R. B.
    Olsen, Dorte Aa
    Ostergaard, Birthe
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
  • [49] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, Tania
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [50] HER2 overexpression in metastatic breast cancer: development of therapies
    Pivot, X.
    Jary, M.
    Dobi, E.
    Bazan, F.
    Chaigneau, L.
    Cals, L.
    Almotlak, H.
    Montcuquet, P.
    Meneveau, N.
    Villanueva, C.
    ONCOLOGIE, 2012, 14 (01) : 37 - 40
12345